Efficacy News and Research

RSS

Combination treatment approach shows promise for hard-to-treat triple-negative breast cancer

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms of breast cancer.

21 Aug 2025

New genome-wide CRISPR screening tool boosts natural killer cells to fight cancer

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from The University of Texas MD Anderson Cancer Center.

21 Aug 2025

New formulation of chemotherapy drug opens doors to advanced cancer treatment options

University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than standard forms of chemotherapy.

21 Aug 2025

Could chlorophyll become the next antidiabetic therapy?

Research highlights chlorophyll's role in blood sugar regulation and insulin mimicry, though safety risks and lack of human trials warrant caution.

20 Aug 2025

Review finds coffee linked to longer life and lower disease risk

A new review highlights that coffee consumption is consistently linked to reduced risks of death, cardiovascular disease, diabetes, and some cancers, while also supporting mental and physical well-being. It also cautions on intake during pregnancy and when sugar or cream are added.

19 Aug 2025

Tenofovir amibufenamide shows efficacy in chronic hepatitis B patients with normal ALT

Chronic hepatitis B virus (HBV)-infected patients may exhibit liver fibrosis and other pathological changes despite normal alanine aminotransferase (ALT).

19 Aug 2025

FAST walk shows promise in improving gait for chronic stroke patients

Stroke remains one of the leading causes of long-term disability worldwide, affecting millions each year.

19 Aug 2025

Improving gene therapy safety with human kidney organoids

Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, "AAV for gene therapy drives a nephrotoxic response via NFκB in kidney organoids."

19 Aug 2025

New strategies to tackle resistant foodborne pathogens

Innovative approaches in food and beverage analysis are transforming pathogen detection and control, emphasizing the role of natural compounds and sequencing.

19 Aug 2025

New nanoparticle drug delivery system targets the spleen for precise lupus treatment

With a $1 million Impact Award from the U.S. Department of Defense, Tianfu Wu, a University of Houston biomedical engineer, is developing a method to send medication directly to the spleen where certain immune cells cause the disease known as lupus, or Systemic Lupus Erythematosus.

18 Aug 2025

Advancing cancer treatment with targeted microrobotic swarms

Cancer remains one of the most challenging diseases to treat, as conventional therapies like chemotherapy and radiotherapy are often hindered by poor specificity, systemic toxicity, and damage to healthy tissues.

18 Aug 2025

Targeting mitochondrial biogenesis to improve outcomes in acute kidney injury

Acute kidney injury (AKI) remains a significant global health challenge, with high mortality rates and the potential for progression to chronic kidney disease.

18 Aug 2025

Exploring the complex origins of endothelial cells in tumor angiogenesis

This newly published review article offers a comprehensive examination of the complexities of tumor angiogenesis and the origins of endothelial cells (ECs) within tumors.

18 Aug 2025

Study shows promising anti-diabetic potential of coffee's functional components

Three of the compounds demonstrated significant inhibitory effects on α-glucosidase, a key enzyme in carbohydrate digestion. The findings could pave the way for new functional food ingredients targeting type 2 diabetes.

18 Aug 2025

New AAV gene therapy reverses age-related macular degeneration

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment. Current first-line treatment for nAMD are anti-VEGF agents, which has shown promising therapeutics outcomes.

18 Aug 2025

Electrophysiology-based strategies enhance cancer immunotherapy

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy.

17 Aug 2025

Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.

17 Aug 2025

Genetically-engineered immune cells show promise for preventing organ rejection

A Medical University of South Carolina team reports in Frontiers in Immunology that it has engineered a new type of genetically modified immune cell that can precisely target and neutralize antibody-producing cells complicit in organ rejection.

17 Aug 2025

New generation of CRISPR shows safer path to treating genetic diseases

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA - often thought to be little more than genetic cobwebs - actively silence genes.

17 Aug 2025

GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP-1R agonists by increasing vascular permeability and targeting appetite-regulating neurons. This mechanism may explain why GIPR/GLP-1R co-agonists outperform single-agent therapies.

14 Aug 2025